FDA Warning Letter Targets Ligand Oncologics
This article was originally published in The Pink Sheet Daily
Executive Summary
DDMAC letter coincides with completion of Eisai’s acquisition of Ligand’s Ontak and Targretin.
You may also be interested in...
3M Warned On Sales Materials For Maxair Autohaler
DDMAC warning letter issued as company nears sale of its pharmaceutical business.
Orapred Website Taken Down After FDA Warning; Corrected Site Will Return
BioMarin’s website for the oral corticosteroid underplayed risk, broadened its indication and made unsubstantiated claims, DDMAC says.
Eisai Eyes Oncology Franchise With Acquisition Of Ligand Products
Company may also hire Ligand personnel in addition to purchase of Ontak, Targretin and Panretin.